Report of Adverse Event Following Immunization (AEFI)

Public | Santé Health | publique Ontario | Ontario

When completed, please send the form to your local <u>Public Health Unit</u> by a secure means. For more information about AEFI reporting in Ontario visit the <u>Public Health Ontario website</u>.

The form should be used to capture AEFIs for all vaccines, including COVID-19 vaccines.

Case ID (for local use only):

1 - CLIENT	INFORMATI	ON												
Client last name: Given				ame(s): Ontario H			Ontario Health	alth Card #:			Date of Birth (yyyy/mm/dd):			
Gender: Male Female Other Unk				known	nown Parent/guardian/caregiver full name, as applicable:				able:	Telephone #:				
Address:					City:					Postal Code:				
Reported to public health by:				Relati	Relationship with case:				Da	Date of report (yyyy/mm/dd):				
Form completed	by:			Conta	ct informati	on (if diffe	rent from above):							
2 - IMMUNIZ	ATION INFO	DRMATIC	N For F	Pfizer-	BioNTech (COVID-1	9 vaccine enter <u>bo</u>	oth vac	ccine ar	nd dil	uent info	ormation	here.	
<u> </u>					ufacturer		Lot # Exp. d			1		Site	Route	
(yyyy/mm/dd) (24hr - HH:MM)							(yyyy/mr			d)			ļ	
										\dashv			-	
	<u> </u>			D		-			\			l		
Immunization e	Yes*	Previous history of No Un				own Yes*			cine administered by:					
	Describe in Se	cribe in Section 5				Describe in Section 5								
Report only even to onset of the	ts which cannot be event (time between	attributed to on vaccine adm d in minutes, i	co-existing ninistration f less than	condition and <u>on</u> 24 hour	ons. Reaction set of each evers record in he	s marked w vent) and th ours, if grea	IONAL COVID-19 V with an asterisk (*) mus ne duration of each ev ater than or equal to 24	t be diag ent in m	gnosed by inutes or ecord in d	a phys hours lays.	sician. Rec or days . I	ord the tin f the interv	ne al /	
1 I D 4'	-4.41				urs or days	1	I- D		Sp			1	or days	
Local Reaction Injection Site		o onset event	Du	ration of event	Allergic Reactions			Time to onset of event		Duration of event				
Pain/redness	ng				Event managed as anaphylaxis									
past nearest j			+		Oculorespiratory syndrome (ORS)			RS)						
Pain/redness / swelling lasting 4 days or more						Allergic reaction - skin (E.g. hives)			es)					
Infected abscess*						Neurologic Events				Time to onset				
Sterile absce					Neurologic Events					event		vent		
Nodule					Convulsions / seizure									
Cellulitis*					Encephalopathy / encephalitis*									
Customia Danas		Time a 4		D.	matian of	Me 1	ningitis*		L					
Systemic Reactions			o onset event	t Duration of event			Anaesthesia / paraesthesia*					-		
Fever greater					Paralysis*						+			
(Only reporta with another						Bell's Palsy*					+			
Rash			1		Guillian-Barré Syndrome (GBS)* Myelitis / Transverse Myelitis*)*			+			
Adenopathy /	/*				1 1	enus / Transverse My ute disseminated	renus	-			+			
Hypotonic-hyporesponsive episode (HHE)*						encephalomyelitis*			L			<u> </u>		
Persistent crying / screaming					Other events of interest					to onset event		ition of vent		
Severe vomiting / diarrhea						Th	Thrombocytopenia*						•	
(3 episodes/24 hours) Parotitis*				+			Arthritis / arthralgia					1		
i di Stitio						J Into	ussusception*							
						Ka	wasaki Disease*							
						Sy	ncope (fainting) with i	njury						
						Oth	ner severe or unusua	levents	: I			1		

4 - COVID-19 ADVERSE EVENT(S) OF SPECIAL INTEREST

In addition to the adverse events listed on the page one, please indicate occurrence of any of the following reactions associated with administration of COVID-19 vaccine. These reactions should only be used for AEFIs reported following receipt of COVID-19 vaccine.

	Specify minutes of	or hours or da	or days Specify minutes or hours or						
COVID-19 AESI	Time to onset of event	Duration of event	f COVID	0-19 AESI	Time to of ev		Duration of event		
Vaccine-associated enhanced		1	Acı	ute kidney injury					
disease		 	— Acı	ute liver injury					
Multisystem inflammatory syndrome in children			And	osmia and / or ageusia					
Acute respiratory distress			Chi	ilblain like lesions					
syndrome			Sin	gle organ cutaneous vascu	ulitis				
Acute cardiovascular injury		 	Ery	thema multiforme					
Coagulation disorder									
5 - COMMENTS FURTHER Please provide a detailed description of medical conditions), concomitant medical indicated in Section 2.	the event including all	ll signs and symp	ptoms, medical hist	tory (e.g. immunocompromis					
6 - HEALTH CARE UTILIZA	ATION & OUT	COME							
Please provide information about health	care utilization relate	d to the event. C	Outcome to be upda	ated by the Public Health uni	t when the invest	tigation is o	complete.		
Medical consultation (non-urgent) Yes	No Date (yyyy/r	mm/dd)		Name and address of health professional attending the event					
Seen in emergency department Yes	No Date (yyyy/r	mm/dd)		Name and address of f	ddress of facility where the event was attended to				
Admitted to hospital Yes because of event	' Yes NO			(e.g., hospital name)	domy niio.o				
	Discharge Date (yyyy/mm/dd)								
OUTCOME Recovered	Not yet red (describe b		Permanent disa (describe below	ability / incapacity /)	Unknown	Death (descri	be below)		
Describe:			Date of outcome: (yyyy/mm/dd)						
7 - MEDICAL OFFICER OF	HEALTH (MC)H) RECOI	MMENDATIO	ONS					
For Public Health Unit use only. To be co	ompleted by the MOH	or designate.							
Check all that apply:	M	MOH recommendation comments:							
No recommendation									
No change to immunization s									
Determine protective antibod									
Active follow-up for AEFI recu	urrence after next v	/accine							
Controlled setting for next im-	munization	M	Medical Officer of Health (MOH) or Designate						
Expert referral (Specify)	N	lame:			Date (yyyy/mm/dd)				
No further immunization (Corcomplete - Specify)		Signature:							

The personal health information provided on this form is collected under the authority of the Health Protection and Promotion Act and O. Reg 569. The personal health information is used to signal adverse events that may require more in-depth investigation and to ensure the continued safety of vaccines on the Canadian market by monitoring adverse events following immunization with vaccines. The information collected may be shared with the Public Health Agency of Canada. If you have questions about the collection of this personal health information please contact your local public health unit.

Other (Specify)

